MAPT and Alzheimer disease: [18F]Flortaucipir uptake correlates with histological findings of AD-related tau pathology [10–12], with phosphorylated tau (p-tau181) in the cerebral spinal fluid (CSF) [13, 14], discriminates between preclinical AD and AD-related dementia (ADRD) [11, 12], and is highly predictive of future cognitive decline and conversion of cognitively normal (CN) and mild cognitive impairment (MCI) to AD [15].